The Influence of Plasma Prekallikrein Oligonucleotide Antisense Therapy on Coagulation and Fibrinolysis Assays: A Post-hoc Analysis

Lauré M. Fijen; Remy S. Petersen; Joost C. M. Meijers; Laura Bordone; Marcel Levi; Danny M. Cohn

doi:10.1055/a-1926-2367

Thrombosis and Haemostasis, Inhaltsverzeichnis

CC BY 4.0 · Thromb Haemost 2022; 122(12): 2045-2049
DOI: 10.1055/a-1926-2367

Letter to the Editor

The Influence of Plasma Prekallikrein Oligonucleotide Antisense Therapy on Coagulation and Fibrinolysis Assays: A Post-hoc Analysis

Lauré M. Fijen

¹Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

,

Remy S. Petersen

¹Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

,

Joost C. M. Meijers

²Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

³Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands

,

Laura Bordone

⁴Ionis Pharmaceuticals, Carlsbad, California, United States

,

Marcel Levi

¹Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

,

Danny M. Cohn

¹Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

References
1 Fijen LM, Riedl MA, Bordone L. et al. Inhibition of prekallikrein for hereditary angioedema. N Engl J Med 2022; 386 (11) 1026-1033
2 Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010; 126 (05) 918-925
3 Jones DH, Bansal P, Bernstein JA. et al. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organ J 2022; 15 (01) 100621
4 Björkqvist J, Jämsä A, Renné T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110 (03) 399-407
5 Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64 (02) 254-257
6 de Maat S, Joseph K, Maas C, Kaplan AP. Blood clotting and the pathogenesis of types I and II hereditary angioedema. Clin Rev Allergy Immunol 2021; 60 (03) 348-356
7 Girolami A, Allemand E, Bertozzi I, Candeo N, Marun S, Girolami B. Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol 2010; 123 (04) 210-214
8 Girolami A, Ferrari S, Cosi E, Girolami B. Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities. Blood Coagul Fibrinolysis 2018; 29 (05) 423-428
9 Girolami A, Rolland C, Sexton D, Vardi M, Bernstein JA. Long-term safety outcomes of prekallikrein (Fletcher factor) deficiency: a systematic literature review of case reports. Allergy Asthma Proc 2020; 41 (01) 10-18
10 Barco S, Sollfrank S, Trinchero A. et al. Severe plasma prekallikrein deficiency: clinical characteristics, novel KLKB1 mutations, and estimated prevalence. J Thromb Haemost 2020; 18 (07) 1598-1617
11 Zhou K, Mehedint D, Khadim H. Prolonged activated partial thromboplastin time due to plasma prekallikrein deficiency: a case study and literature review on its clinical significance. Blood Coagul Fibrinolysis 2019; 30 (06) 300-303
12 Schmaier AH. Plasma prekallikrein: its role in hereditary angioedema and health and disease. Front Med (Lausanne) 2018; 5: 3
13 Stavrou EX, Fang C, Merkulova A. et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood 2015; 125 (04) 710-719
14 Revenko AS, Gao D, Crosby JR. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118 (19) 5302-5311
15 Bird JE, Smith PL, Wang X. et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107 (06) 1141-1150
16 Thompson RE, Mandle Jr R, Kaplan AP. Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci U S A 1979; 76 (10) 4862-4866
17 Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342 (10) 696-701
18 Suri MF, Yamagishi K, Aleksic N, Hannan PJ, Folsom AR. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis 2010; 29 (05) 497-502
19 Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108 (13) 4045-4051
20 Rohmann JL, Huo S, Sperber PS. et al. Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke. J Thromb Haemost 2020; 18 (12) 3316-3324
21 Schmaier AH, Bauer KA, Cicardi M. et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. J Allergy Clin Immunol 2019; 143 (02) AB41
22 Colman RW, Bagdasarian A, Talamo RC. et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56 (06) 1650-1662
23 Krijanovski Y, Proulle V, Mahdi F, Dreyfus M, Müller-Esterl W, Schmaier AH. Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. Blood 2003; 101 (11) 4430-4436
24 Schapira M, Scott CF, James A. et al. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry 1982; 21 (03) 567-572
25 Scott CF, Colman RW. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 1980; 65 (02) 413-421